-
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
-
Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations
-
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
-
Ultimovacs ASA: Annual Report 2022
-
Ultimovacs to Present at Cowen Healthcare Conference
-
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation
-
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma
-
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial
-
Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer
